標(biāo)題: Titlebook: Gene Therapy for Neurological Disorders; Methods and Protocol Fredric P. Manfredsson Book 2016 Springer Science+Business Media New York 201 [打印本頁(yè)] 作者: 作業(yè) 時(shí)間: 2025-3-21 18:45
書(shū)目名稱Gene Therapy for Neurological Disorders影響因子(影響力)
書(shū)目名稱Gene Therapy for Neurological Disorders影響因子(影響力)學(xué)科排名
書(shū)目名稱Gene Therapy for Neurological Disorders網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱Gene Therapy for Neurological Disorders網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱Gene Therapy for Neurological Disorders被引頻次
書(shū)目名稱Gene Therapy for Neurological Disorders被引頻次學(xué)科排名
書(shū)目名稱Gene Therapy for Neurological Disorders年度引用
書(shū)目名稱Gene Therapy for Neurological Disorders年度引用學(xué)科排名
書(shū)目名稱Gene Therapy for Neurological Disorders讀者反饋
書(shū)目名稱Gene Therapy for Neurological Disorders讀者反饋學(xué)科排名
作者: 失敗主義者 時(shí)間: 2025-3-21 22:52
Small-Scale Recombinant Adeno-Associated Virus Purification purification from ten to twenty 15 cm plates of human embryonic kidney-derived 293B cells (HEK 293) cells that can yield approximately 300 μl of a 5?×?10. to 1?×?10. genome copies/ml viral preparation final concentration.作者: 干旱 時(shí)間: 2025-3-22 03:42 作者: 寬大 時(shí)間: 2025-3-22 06:11
Jianshan Yang,Kun Luo,Yun Bai,JianRen Fanerapeutic factors to distinct brain cell populations are discussed, followed by a detailed description of the setscrews that are available for these experiments. A critical discussion of current stumbling blocks and necessary developments to achieve clinical applicability of advanced targeted vector systems is provided.作者: 使痛苦 時(shí)間: 2025-3-22 12:46
https://doi.org/10.1007/978-1-4842-2793-0expression has its own strengths and limitations, which makes them more or less suitable for different applications. In this chapter, we describe the available alternatives and provide tips on how they can be implemented.作者: NATAL 時(shí)間: 2025-3-22 14:40
The Product Life Cycle Analysis Revisitedile, and can be easily modified to fit the specific needs of the researcher in order to produce relatively high-titer LV vectors which can be used to transduce a wide variety of cells both in vitro and in vivo.作者: NATAL 時(shí)間: 2025-3-22 18:19
S. Ferson,L. R. Ginzburg,R. A. Goldstein of virions for which each particular capsid variant is matched with the particular capsid gene encoding it; recovery of capsid gene sequences from target tissue after systemic administration. Prevalent variants are then analyzed and evaluated.作者: PALSY 時(shí)間: 2025-3-23 01:03 作者: Reservation 時(shí)間: 2025-3-23 01:40 作者: 格言 時(shí)間: 2025-3-23 09:20
Lentivirus Production and Purificationile, and can be easily modified to fit the specific needs of the researcher in order to produce relatively high-titer LV vectors which can be used to transduce a wide variety of cells both in vitro and in vivo.作者: Gorilla 時(shí)間: 2025-3-23 12:00
Altering Tropism of rAAV by Directed Evolution of virions for which each particular capsid variant is matched with the particular capsid gene encoding it; recovery of capsid gene sequences from target tissue after systemic administration. Prevalent variants are then analyzed and evaluated.作者: contrast-medium 時(shí)間: 2025-3-23 13:54 作者: FLINT 時(shí)間: 2025-3-23 18:39 作者: Chromatic 時(shí)間: 2025-3-24 00:49 作者: Surgeon 時(shí)間: 2025-3-24 04:48 作者: Allodynia 時(shí)間: 2025-3-24 08:04 作者: 機(jī)制 時(shí)間: 2025-3-24 10:50 作者: Odyssey 時(shí)間: 2025-3-24 16:14
Norbert Clauer,Sambhu Chaudhuriiverse diseases including hemophilia B and Leber’s congenital amaurosis. In addition to rAAV’s high efficiency of transduction and the capacity for long-term transgene expression, the safety profile of rAAV remains unsoiled in humans with no deleterious vector-related consequences observed thus far.作者: 緊張過(guò)度 時(shí)間: 2025-3-24 21:40 作者: addict 時(shí)間: 2025-3-25 02:14 作者: 征服 時(shí)間: 2025-3-25 04:02 作者: 壯觀的游行 時(shí)間: 2025-3-25 11:33
Jianshan Yang,Kun Luo,Yun Bai,JianRen Fanal targeting is first discussed in the context of vector tropism and appropriate delivery. Then, some of our own attempts to restrict expression of therapeutic factors to distinct brain cell populations are discussed, followed by a detailed description of the setscrews that are available for these e作者: FLOUR 時(shí)間: 2025-3-25 11:52 作者: NADIR 時(shí)間: 2025-3-25 17:37 作者: 發(fā)芽 時(shí)間: 2025-3-25 20:07 作者: 庇護(hù) 時(shí)間: 2025-3-26 01:40
Clean Technology and the Environment an array of techniques for modification of the viral capsid. AAV capsid variants possess unique antigenic profiles and demonstrate distinct cellular tropisms driven by differences in receptor binding. AAV capsids can be chemically modified to alter tropism, can be produced as hybrid vectors that co作者: 是突襲 時(shí)間: 2025-3-26 07:05 作者: 動(dòng)機(jī) 時(shí)間: 2025-3-26 09:58
https://doi.org/10.1007/978-3-642-30445-3udotyping of lentiviral vectors with different envelope glycoproteins not only confers the neurotropism to the vectors, but also alters the preference of sites of vector entry into neuronal cells. One major group of lentiviral vectors is a pseudotype with vesicular stomatitis virus glycoprotein (VSV作者: CAGE 時(shí)間: 2025-3-26 15:39
https://doi.org/10.1007/978-3-030-23165-1etic or natural antivirals, expand tropism, or alter virulence. Recently, mutations to the human adenovirus polymerase that reduce replicative fidelity were described, and we have incorporated one of these mutations into the . gene of a conditionally replicating human adenovirus serotype 5 (HAdV-5)-作者: candle 時(shí)間: 2025-3-26 17:24 作者: constitutional 時(shí)間: 2025-3-26 22:57 作者: Chivalrous 時(shí)間: 2025-3-27 02:35 作者: 星星 時(shí)間: 2025-3-27 08:55 作者: 帶子 時(shí)間: 2025-3-27 09:40
Gene Therapy for Neurological Disorders978-1-4939-3271-9Series ISSN 1064-3745 Series E-ISSN 1940-6029 作者: 繞著哥哥問(wèn) 時(shí)間: 2025-3-27 14:43 作者: florid 時(shí)間: 2025-3-27 17:51
Intraparenchymal Stereotaxic Delivery of rAAV and Special Considerations in Vector Handlingpowerful tool that provides the ability to manipulate gene expression in specific regions, or even specific cell types in the brain. Here, we describe the proper handling and stereotaxic delivery of recombinant adeno-associated virus to various neuroanatomical structures of the rodent brain.作者: 射手座 時(shí)間: 2025-3-27 22:44
Introduction to Viral Vectors and Other Delivery Methods for Gene Therapy of the Nervous Systeme practical application of viral or non-viral gene therapy is not as straightforward as it may seem. All too often investigators see their experiments fail due to low-quality third-party vectors or due to a lack of knowledge regarding the proper use of these tools. For example, researchers often fin作者: insular 時(shí)間: 2025-3-28 05:16
Delivering Transgenic DNA Exceeding the Carrying Capacity of AAV Vectorsiverse diseases including hemophilia B and Leber’s congenital amaurosis. In addition to rAAV’s high efficiency of transduction and the capacity for long-term transgene expression, the safety profile of rAAV remains unsoiled in humans with no deleterious vector-related consequences observed thus far.作者: nephritis 時(shí)間: 2025-3-28 07:40 作者: Meditate 時(shí)間: 2025-3-28 14:05 作者: 蠟燭 時(shí)間: 2025-3-28 17:41 作者: 艦旗 時(shí)間: 2025-3-28 19:58
Tissue-Specific Promoters in the CNSal targeting is first discussed in the context of vector tropism and appropriate delivery. Then, some of our own attempts to restrict expression of therapeutic factors to distinct brain cell populations are discussed, followed by a detailed description of the setscrews that are available for these e作者: 不開(kāi)心 時(shí)間: 2025-3-29 02:39
Small-Scale Recombinant Adeno-Associated Virus Purificationr and long-term expression in tissues including brain. In addition, rAAV has demonstrated an impressive safety profile in gene therapy trials. The emergence of rAAV serotypes with different cell tropisms and distribution properties has allowed scientists to tailor serotypes to specific experimental 作者: RAFF 時(shí)間: 2025-3-29 07:05 作者: 哺乳動(dòng)物 時(shí)間: 2025-3-29 10:23 作者: squander 時(shí)間: 2025-3-29 13:28
Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids an array of techniques for modification of the viral capsid. AAV capsid variants possess unique antigenic profiles and demonstrate distinct cellular tropisms driven by differences in receptor binding. AAV capsids can be chemically modified to alter tropism, can be produced as hybrid vectors that co作者: Monocle 時(shí)間: 2025-3-29 19:25
Altering Tropism of rAAV by Directed Evolutionnvolves the generation of an initial library of high complexity followed by cycles of selection during which the library is progressively enriched for target-specific variants. Each selection cycle consists of the following: reconstitution of complete AAV genomes within plasmid molecules; production作者: RACE 時(shí)間: 2025-3-29 23:33
Altering Entry Site Preference of Lentiviral Vectors into Neuronal Cells by Pseudotyping with Enveloudotyping of lentiviral vectors with different envelope glycoproteins not only confers the neurotropism to the vectors, but also alters the preference of sites of vector entry into neuronal cells. One major group of lentiviral vectors is a pseudotype with vesicular stomatitis virus glycoprotein (VSV作者: Nomogram 時(shí)間: 2025-3-30 00:37 作者: Lobotomy 時(shí)間: 2025-3-30 04:41
Intraparenchymal Stereotaxic Delivery of rAAV and Special Considerations in Vector Handlingpowerful tool that provides the ability to manipulate gene expression in specific regions, or even specific cell types in the brain. Here, we describe the proper handling and stereotaxic delivery of recombinant adeno-associated virus to various neuroanatomical structures of the rodent brain.作者: 嘲笑 時(shí)間: 2025-3-30 08:55
Diagenesis and Very Low-Grade Metamorphism,nology. This includes understanding how to appropriately design and execute an experiment, understanding various delivery vehicles (e.g., what virus to use), delivery methods (e.g., systemic versus intracranial injections), what expression system to use, and the time course involved with a particula作者: 不適當(dāng) 時(shí)間: 2025-3-30 12:40 作者: Antarctic 時(shí)間: 2025-3-30 17:53
Advanced Concepts of Modern C++,of transgenes using antibiotics are commonly used to control either gene expression using tetracycline-controlled transcription or protein levels using destabilizing domain technology. Alternatively, specific promoters of genes that are regulated by disease mechanisms, increasing expression as the d作者: adjacent 時(shí)間: 2025-3-30 22:16
https://doi.org/10.1007/978-3-030-68502-7efore being exported to the cytoplasm. These molecules can then be incorporated into the RNA-induced silencing complex (RISC) which utilizes sequence complementarity to recognize target mRNAs and activate either translational repression, in the case of partial complementarity, or induce mRNA cleavag作者: FRET 時(shí)間: 2025-3-31 04:51
Clean Technology and the Environmentdes a varied toolkit for gene delivery to the CNS and retina, with specialized vectors available for many applications, but selecting a capsid variant from the array of available vectors can be difficult. This chapter describes the unique properties of a range of AAV variants and engineered capsids,
